Literature DB >> 23551149

Hereditary amyloidosis caused by R554L fibrinogen Aα-chain mutation in a Spanish family and review of the literature.

Michael Haidinger1, Johannes Werzowa, Renate Kain, Marlies Antlanger, Manfred Hecking, Stefan Pfaffenberger, Julia Mascherbauer, Thomas Gremmel, Janet A Gilbertson, Dorota Rowczenio, Thomas Weichhart, Chantal Kopecky, Walter H Hörl, Philip N Hawkins, Marcus D Säemann.   

Abstract

BACKGROUND: Hereditary amyloidosis with predominant renal disease can be caused by mutations in the gene encoding the fibrinogen Aα-chain (AFib). Here, we describe the clinical course of AFib amyloidosis associated with the rare R554L mutation, and the significance of extrarenal amyloid deposits and their possible influence on cardiovascular morbidity.
METHODS: We report on 101 members of a family after having conducted patient interviews, chart review, genetic testing, renal biopsies and assessment for extrarenal amyloid deposition.
RESULTS: Ten family members had chronic kidney disease with late-onset gross proteinuria and a variable course of declining renal function, starting in the fourth decade of life. In two affected living members, we identified the AFib R554L mutation. Renal biopsies from two affected members revealed almost complete obliteration of the mesangial glomerular architecture, although kidney function was only moderately impaired. There was neither evidence of extrarenal amyloidosis nor accelerated atherosclerosis.
CONCLUSIONS: Renal amyloidosis associated with the R554L AFib variant dominated the clinical picture in this family, which was similar to that associated with the much more prevalent E526V mutation. Although it has been hypothesized that vascular deposits of fibrinogen amyloid may be associated with accelerated atherosclerosis, there was no suggestion of this in this particular kindred.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23551149     DOI: 10.3109/13506129.2013.781998

Source DB:  PubMed          Journal:  Amyloid        ISSN: 1350-6129            Impact factor:   7.141


  5 in total

1.  Lipopolysaccharide-binding protein (LBP) can reverse the amyloid state of fibrin seen or induced in Parkinson's disease.

Authors:  Etheresia Pretorius; Martin J Page; Sthembile Mbotwe; Douglas B Kell
Journal:  PLoS One       Date:  2018-03-01       Impact factor: 3.240

Review 2.  To What Extent Are the Terminal Stages of Sepsis, Septic Shock, Systemic Inflammatory Response Syndrome, and Multiple Organ Dysfunction Syndrome Actually Driven by a Prion/Amyloid Form of Fibrin?

Authors:  Douglas B Kell; Etheresia Pretorius
Journal:  Semin Thromb Hemost       Date:  2017-08-04       Impact factor: 4.180

Review 3.  A central role for amyloid fibrin microclots in long COVID/PASC: origins and therapeutic implications.

Authors:  Douglas B Kell; Gert Jacobus Laubscher; Etheresia Pretorius
Journal:  Biochem J       Date:  2022-02-17       Impact factor: 3.857

4.  Fibrinogen A Alpha-Chain Amyloidosis in Two Chinese Patients.

Authors:  Zhen-Yu Li; Shuang Wang; Dan-Yang Li; Dan Liu; Su-Xia Wang; Xiao-Juan Yu; Gang Liu; Fu-De Zhou; Ming-Hui Zhao
Journal:  Front Med (Lausanne)       Date:  2022-04-28

5.  Lipopolysaccharide-binding protein (LBP) reverses the amyloid state of fibrin seen in plasma of type 2 diabetics with cardiovascular co-morbidities.

Authors:  Etheresia Pretorius; Sthembile Mbotwe; Douglas B Kell
Journal:  Sci Rep       Date:  2017-08-29       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.